+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceutical Spray Drying Market (2nd Edition), 2018-2028

  • PDF Icon

    Report

  • 200 Pages
  • April 2018
  • Region: Global
  • Roots Analysis
  • ID: 4542473

The origins of spray drying can be traced back to 1872, when the first patent related to the technique was registered in the US. The first commercial use of this form of drying was reported in the 1920s when powdered milk was introduced into the market. Spray drying, which is already established in the food and chemical sector, is also considered to be a rapid, cost-effective, and scalable process for the production of dry powder formulations of pharmacological material. Owing to characteristics, such as reproducibility and its continuous mode of operation, the technique has become very popular in the pharmaceutical and biotechnology industry.

It offers several advantages over alternate drying technologies, such as lyophilization (characterized by high dependence on cold chain for storage and logistics, which is prone to failure due to human error) and vacuum foam drying (characterized by volumetric restrictions due to the properties of foam, which limits the quantity of sample that can be dried in a single run) that are currently deployed in the pharmaceutical industry.

Amongst other merits, spray drying is known to be suitable for drying heat-sensitive products such as biologics. Moreover, this method imparts improved properties to the formulations that can be administered through more efficient and less invasive modes of delivery, such as oral, and inhalation routes. The technology also aids in improving the compression properties of drugs, allowing developers to design concentrated dose variants of medications and reduce tablet size. Such alterations have the potential to improve patient compliance. Given the flexibility offered in terms of drug development and formulation, the economics of the technique, the introduction of aseptic methods, and the recent approval of the first spray dried biologic, Raplixa®, the adoption of spray drying is anticipated to increase steadily in the pharmaceutical industry.

The ‘Pharmaceutical Spray Drying Market (2nd Edition), 2018-2028’ report provides an extensive study on the use of spray drying in the pharmaceutical sector. The key focus of the report is primarily to estimate the future potential of spray drying in the manufacturing of APIs, inhalables, injectables, biologics and other pharmaceutical products. The study presents an in-depth analysis of a diverse set of companies that provide spray drying equipment and services across different regions of the globe.

Amongst other elements, the report includes:


  • A detailed discussion the applications of spray drying in the pharmaceutical industry; these include enhancement of solubility and bioavailability, formulation of inhalables, taste masking, development of controlled release formulations, and aseptic production of biopharmaceuticals.
  • An assessment of the various players that are engaged in the manufacturing of spray dryers used in the pharmaceutical industry, including a detailed analysis of their products based on inlet temperature, type of nozzle (fluid, pressure, rotary disc, centrifugal and others), size of the dryer (lab, clinical and commercial) and atomizing gas (air, nitrogen and inert gases).
  • An overview of the current market landscape of spray drying service providers, featuring an analysis based on the location of their operating facilities, type of spray dryers used, scale of operation (lab, clinical and commercial), information on cGMP status of their facilities and availability of fill/finish services.
  • An insightful 2X2 analysis of different spray drying service providers. This analysis is based on the spray drying capabilities (represented in terms of number of manufacturing sites, scale of operation and the types of spray dryers used) and the company size. In addition, similar analysis has been done to compare the spray dryer manufacturers. This assessment is based on the company’s spray drying portfolio (number of spray dryers offered and availability of spray drying services), company’s year of establishment and the geographical coverage of its client base.
  • Tabulated profiles of the players offering spray drying services, featuring company overview, service portfolio, spray dryers used, and key developments related to its spray drying capabilities.
  • Detailed profiles of spray dryer manufacturers, featuring an overview of the company, its financial information (if available), types of spray dryers in their respective product portfolios, recent developments and a comprehensive future outlook.
  • A case study on the lyophilization of biologics, highlighting the underlying process, its applications, and merits and demerits. It features a detailed list of companies offering lyophilization services with information on location of facilities, types of drug candidates lyophilized, scale of operation and the containment systems utilized for such operations.
  • A detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired in the last few years, along with the geographical distribution of this activity. The analysis highlights the ownership change matrix and presents financial evaluation of these deals (revenues and respective deal multiples).
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as trends in the pharmaceutical contract manufacturing industry, operation costs associated with spray drying and the challenges and opportunities presented by this technique, we have provided an informed estimate of the likely evolution of the market in the long term, for the period 2018-2028. In addition, we have provided insights on the likely regional evolution of the market in North America, Europe, Asia Pacific and the rest of the world. It also includes estimates regarding the likely distribution of the market based on type of industry (pharmaceuticals and biologics) and type of nozzles used in spray dryers (fluid nozzle, pressure nozzle, rotary disc atomizer, centrifugal nozzle, and others). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain.

The report features detailed transcripts of interviews held with the following key opinion leaders:


  • Sam de Costa (Stabilization Projects Manager, Nova Laboratories)
  • Manuel Leal (Business Development Director, Idifarma)
  • Anonymous (Founder, India based Manufacturer)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights


  • Over 50 companies are offering spray drying services for pharmaceutical products. At present, the market is highly fragmented and features a mix of established companies (>500 employees, 48%), mid-sized companies (51-500 employees, 27%) and small-sized companies (<50 employees, 25%). Of the total number of service providers, 26 companies offer spray drying services at all three (laboratory, clinical and industrial) scales of operation. Examples of these companies include (in alphabetical order, no selection criteria) Catalent Pharma Solutions, Evotec, Patheon, Pulse Combustion Systems and Siegfried.
  • The market is also characterized by presence of over 20 manufacturers that have, so far, developed 86 spray dryers for use in the pharmaceutical industry. Of these, 35% of companies are established players, 30% are mid-sized companies and 35% are small-sized companies. Majority of the spray dryers being developed by these manufacturers (38%) use a fluid nozzle (particularly 2-fluid nozzles), while others use rotary disc atomizers (8%), and centrifugal (7%) and pressure nozzles (7%). Interestingly, the rest of the spray dryers are compatible with multiple nozzle types.
  • With respect to maximum inlet temperature, most of the spray dryers (48%) can operate at temperatures ranging from 151?C to 250?C. Around 11% of the dryers have maximum inlet temperatures of more than 350?C. Of all the systems that we identified, 70% use air as the atomizing gas. However, in the rest (30%) of the spray dryers, the mode of operation is aseptic and is carried out in a closed loop configuration, using nitrogen or other inert gases.
  • A significant number of companies (close to 70% of the facilities captured in our database) offering pharmaceutical spray drying services are based in North America and Europe. Notable examples of mid-sized and small-sized players based in North America and the US include (in alphabetical order) Coriolis Pharma, Formurex, Leukocare, North Star Processing, Norwich Pharmaceuticals, Nova Laboratories, PacMoore, Richman Chemical, Spray-Tek, Summit Custom Spray Drying, Ufag Laboratorien, Upperton and Vectura. Within Europe, majority of the contract service providers are located in Italy, Germany, France, Spain and the UK. Examples of established players that have business operations in these geographies include (in alphabetical order) AMRI Global, Capsugel (now a part of Lonza), Catalent Pharma Solutions, Juniper Pharma Services and Siegfried. Asia Pacific has 25% of the players offering spray drying services for pharmaceuticals, while 6% of service providers are based in Africa, Latin America, South America and rest of the world.
  • Several CMOs (close to 30) have installed spray dryers developed by GEA Niro in their facilities. Amongst the 15 types of spray dryers offered by GEA Niro, its PSD and GEA Niro Mobile Minor™ models are most commonly used. In addition, spray dryers developed by Buchi (B-290 and B-90 models) are being used by a number of service providers. Spray dryers offered by SPX and ProCepT are also gaining popularity amongst the service providers.
  • We expect the pharmaceutical spray drying services market to grow at an annualized rate of ~20% between 2018 and 2028. North America (primarily US) and Europe currently capture the largest market share (close to 70%) in the spray drying contract services market. This is followed by Asia Pacific and rest of the world. Markets in Asia-Pacific are expected to grow at a relatively higher CAGR owing to inherent advantages such as relatively low labor costs and less stringent regulatory constraints.
  • The current market is driven, to a large extent (over 80%), by pharmaceutical products (such as APIs and intermediate products). The future advances will be jointly led by the steady rise of the biopharmaceuticals’ market; emergence of new technologies/applications is likely to provide the necessary impetus to fuel this growth.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Manufacturers in the Contract Manufacturing Industry
3.3. An Overview of the Pharmaceutical Contract Manufacturing Industry
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1. Traditional CMOs
3.4.2. Modern CMOs
3.5. The Need for Outsourcing in the Pharmaceutical Industry
3.6. Recent Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical Partnership
3.6.2. Integrated End-to-End Business Model
3.6.3. Strategic Long-Term Alliance
3.6.4. Flexible Short-Term Partnership
3.6.5. Software Service Providers
3.7. Services Offered by CMOs
3.8. Selecting a CMO Partner
3.9. Risks and Challenges in Contract Manufacturing Industry
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical CMOs: List of Industry Players
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Type of Business Segment
4.2.5. Distribution by Type of FDF Offered
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Type of Service Offering
4.2.8. Distribution by Location of Manufacturing Facilities
4.2.9. Distribution by Type of Primary Packaging Form Offered
5. REGULATORY LANDSCAPE FOR PHARMACEUTICAL CONTRACT MANUFACTURERS
5.1. Chapter Overview
5.2. Regulatory Guidelines in North America
5.2.1. The US Scenario
5.2.2. Canadian Scenario
5.3. Regulatory Guidelines in Europe
5.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
5.4.1. Chinese Scenario
5.4.2. Indian Scenario
5.4.3. Japanese Scenario
5.4.4. South Korean Scenario
5.4.5. Australian Scenario
5.4.6. Brazilian Scenario
5.5. Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
5.6. Bubble Analysis: Regional Regulatory Summary
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Importance of One-Stop-Shops
6.3. Company Profiles of One-Stop-Shops
6.4. Players in North America
6.4.1. Albany Molecular Research (AMRI)
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Financial Information
6.4.1.4. Manufacturing Capabilities and Facilities
6.4.1.5. Recent Developments
6.4.1.6. Future Outlook
6.4.2. Catalent® Pharma Solutions
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Financial Information
6.4.2.4. Manufacturing Capabilities and Facilities
6.4.2.5. Recent Developments
6.4.2.6. Future Outlook
6.4.3. DPT® Laboratories
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments
6.4.3.5. Future Outlook
6.4.4. Thermo Fisher Scientific (Through Acquisition of Patheon®)
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Financial Information
6.4.4.4. Manufacturing Capabilities and Facilities
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook
6.5. Players in Europe
6.5.1. Aenova Group
6.5.1.1. Company Overview
6.5.1.2. Service Portfolio
6.5.1.3. Financial Information
6.5.1.4. Manufacturing Capabilities and Facilities
6.5.1.5. Recent Developments
6.5.1.6. Future Outlook
6.5.2. Almac Group
6.5.2.1. Company Overview
6.5.2.2. Service Portfolio
6.5.2.3. Recent Developments
6.5.2.4. Future Outlook
6.5.3. CordenPharma
6.5.3.1. Company Overview
6.5.3.2. Service Portfolio
6.5.3.3. Manufacturing Capabilities and Facilities
6.5.3.4. Recent Developments
6.5.3.5. Future Outlook
6.5.4. Fresenius Kabi
6.5.4.1. Company Overview
6.5.4.2. Service Portfolio
6.5.4.3. Financial Information
6.5.4.4. Manufacturing Capabilities and Facilities
6.5.4.5. Recent Developments
6.5.4.6. Future Outlook
6.5.5. Glatt®
6.5.5.1. Company Overview
6.5.5.2. Service Portfolio
6.5.5.3. Manufacturing Capabilities and Facilities
6.5.5.4. Recent Developments
6.5.5.5. Future Outlook
6.5.6. Groupe SYNERLAB
6.5.6.1. Company Overview
6.5.6.2. Service Portfolio
6.5.6.3. Manufacturing Capabilities and Facilities
6.5.6.4. Future Outlook
6.5.7. Hovione
6.5.7.1. Company Overview
6.5.7.2. Service Portfolio
6.5.7.3. Manufacturing Capabilities and Facilities
6.5.7.4. Recent Developments
6.5.7.5. Future Outlook
6.5.8. Recipharm
6.5.8.1. Company Overview
6.5.8.2. Service Portfolio
6.5.8.3. Financial Information
6.5.8.4. Manufacturing Capabilities and Facilities
6.5.8.5. Recent Developments
6.5.8.6. Future Outlook
6.5.9. Siegfried
6.5.9.1. Company Overview
6.5.9.2. Service Portfolio
6.5.9.3. Financial Information
6.5.9.4. Manufacturing Capabilities and Facilities
6.5.9.5. Recent Developments
6.5.9.6. Future Outlook
6.6. Players in Asia-Pacific
6.6.1. CMIC Group
6.6.1.1. Company Overview
6.6.1.2. Service Portfolio
6.6.1.3. Financial Information
6.6.1.4. Manufacturing Capabilities and Facilities
6.6.1.5. Recent Developments
6.6.1.6. Future Outlook
6.6.2. Nectar Lifesciences
6.6.2.1. Company Overview
6.6.2.2. Service Portfolio
6.6.2.3. Financial Information
6.6.2.4. Manufacturing Capabilities and Facilities
6.6.2.5. Future Outlook
6.6.3. WuXi AppTec
6.6.3.1. Company Overview
6.6.3.2. Service Portfolio
6.6.3.3. Financial Information
6.6.3.4. Manufacturing Capabilities and Facilities
6.6.3.5. Recent Developments
6.6.3.6. Future Outlook
7. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
7.1. Chapter Overview
7.2. Small Molecules and Large Molecules Drugs/Therapies
7.2.1. Comparison of Key Characteristics
7.2.2. Comparison of Manufacturing Processes
7.2.3. Comparison of Key Manufacturing Challenges
7.3. Manufacturing of Large Molecules (Biologics): List of Biopharmaceutical CMOs
8. KEY INSIGHTS
8.1. Chapter Overview
8.2. Multipotentialite Service Providers: Heat Map Analysis
8.3. Pharmaceutical CMOs: Geographical Landscape
8.4. Pharmaceutical CMOs: Analysis by Geography, Company Size and Business Segment
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Pharmaceutical Contract Manufacturing: Installed Global Capacity
9.3.1. Distribution by Size of CMOs
9.3.2. Distribution by Scale of Operation
9.3.3. Distribution by Location of Headquarters
9.3.4. Distribution by Location of Manufacturing Facilities
9.4. Concluding Remarks
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Pharmaceutical Contract Manufacturing Market, 2018-2028
10.3.1. Pharmaceutical Contract Manufacturing Market for API Manufacturing, 2018-2028
10.3.2. Pharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2018-2028
10.4. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions
10.4.1. Pharmaceutical Contract Manufacturing Market in North America, 2018-2028
10.4.1.1. Pharmaceutical Contract Manufacturing Market in the US, 2018-2028
10.4.1.2. Pharmaceutical Contract Manufacturing Market in Canada, 2018-2028
10.4.1.3. Pharmaceutical Contract Manufacturing Market in Mexico, 2018-2028
10.4.2. Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028
10.4.2.1. Pharmaceutical Contract Manufacturing Market in Italy, 2018-2028
10.4.2.2. Pharmaceutical Contract Manufacturing Market in Germany, 2018-2028
10.4.2.3. Pharmaceutical Contract Manufacturing Market in France, 2018-2028
10.4.2.4. Pharmaceutical Contract Manufacturing Market in Spain, 2018-2028
10.4.2.5. Pharmaceutical Contract Manufacturing Market in the UK, 2018-2028
10.4.2.6. Pharmaceutical Contract Manufacturing Market in Rest of Europe, 2018-2028
10.4.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028
10.4.3.1. Pharmaceutical Contract Manufacturing Market in India, 2018-2028
10.4.3.2. Pharmaceutical Contract Manufacturing Market in China, 2018-2028
10.4.3.3. Pharmaceutical Contract Manufacturing Market in Japan, 2018-2028
10.4.3.4. Pharmaceutical Contract Manufacturing Market in Australia, 2018-2028
10.4.3.5. Pharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2018-2028
10.4.4. Pharmaceutical Contract Manufacturing Market in Rest of the World, 2018-2028
10.4.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions
10.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product
10.6. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API
10.7. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF
10.7.1. Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028
10.7.2. Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028
10.7.3. Pharmaceutical Contract Manufacturing Market for Semi-Solid/Liquid Form FDF, 2018-2028
10.8. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form
10.8.1. Pharmaceutical Contract Manufacturing Market for Tablets/Capsules/Blister Packing, 2018-2028
10.8.2. Pharmaceutical Contract Manufacturing Market for Glass/Plastic/Dropper Bottles, 2018-2028
10.8.3. Pharmaceutical Contract Manufacturing Market for Vials/Cartridges, 2018-2028
10.8.4. Pharmaceutical Contract Manufacturing Market for Ointments/Gels/Tubes, 2018-2028
10.8.5. Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028
10.8.6. Pharmaceutical Contract Manufacturing Market for Sachets/Pouches/Bags, 2018-2028
10.8.7. Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028
10.9. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers
10.10 Concluding Remarks
11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Comparison of SWOT Factors
12. FUTURE OF THE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
12.1. Chapter Overview
12.2. Anticipated Growth in Outsourcing Activities
12.3. Growing Focus on Emerging Markets
12.4. Expansion of Capabilities and Emergence of One-Stop-Shops
12.5. Adoption of New Technologies and Focus on Innovation to Support Further Growth
12.6. Use of Big Data and Advanced Analytics to Improve Manufacturing Processes
12.7. Implementation of Cybersecurity Solutions to Safeguard Valuable Customer Data
12.8. Concluding Remarks
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Ajinomoto Althea
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Scott Goldstein, Associate Director, Drug Product Manufacturing
13.3. Bachem
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Thomas Früh, Chief Executive Officer
13.4. Sovereign Pharma
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Piyush Desai, Director, Operations
13.5. Batavia Biosciences
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Claire Otjes, Assistant Marketing Manager
13.6. Polymun Scientific
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Dietmar Katinger, Chief Executive Officer
13.7. Rentschler Biopharma
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Birgit Schwab, Senior Manager Strategic Marketing
13.8. WACKER Biotech
13.8.1. Company Snapshot
13.8.2. Interview Transcript: Sebastian Schuck, Head of Business Development
13.9. CiVentiChem
13.9.1. Company Snapshot
13.9.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
13.10. CordenPharma
13.10.1. Company Snapshot
13.10.2. Interview Transcript: Roberto Margartia, Business Development Director
13.11. Helsinn Group
13.11.1. Company Snapshot
13.11.2. Interview Transcript: Allison Vavala, Senior Manager, Business Development
13.12. Novasep
13.12.1. Company Snapshot
13.12.2. Interview Transcript: Kevin Daley, Market Director Pharmaceuticals
14. APPENDIX 1: TABULATED DATA15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Types of Manufacturers in Contract Manufacturing Industry
Figure 3.2 Types of Third-Party Service Providers in the Pharmaceutical Contract Manufacturing Industry
Figure 3.3 Outsourcing across Various Components of Pharmaceutical Value Chain
Figure 3.4 Range of Services Offered by CMOs
Figure 3.5 Factors for Selecting a CMO Partner
Figure 4.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 4.2 Pharmaceutical CMOs: Distribution by Geographical Location
Figure 4.3 Pharmaceutical CMOs: Regional Hubs
Figure 4.4 Pharmaceutical CMOs: Distribution by Company Size
Figure 4.5 Pharmaceutical CMOs: Distribution by Type of Business Segment
Figure 4.6 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Figure 4.7 Pharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.8 Pharmaceutical CMOs: Distribution by Type of Service Offering
Figure 4.9 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Figure 4.10 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Figure 5.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 5.2 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Figure 5.3 Bubble Analysis: Regional Regulatory Summary
Figure 6.1 AMRI: Service Portfolio
Figure 6.2 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.3 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.4 Catalent® Pharma Solutions: Service Portfolio
Figure 6.5 Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Figure 6.6 DPT® Laboratories: Service Portfolio
Figure 6.7 Patheon®: Service Portfolio
Figure 6.8 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Figure 6.9 Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Figure 6.10 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 6.11 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Figure 6.12 Aenova Group: Service Portfolio
Figure 6.13 Almac Group: Service Portfolio
Figure 6.14 CordenPharma: Service Portfolio
Figure 6.15 Fresenius Kabi: Service Portfolio
Figure 6.16 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Figure 6.17 Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Figure 6.18 Glatt®: Service Portfolio
Figure 6.19 Groupe SYNERLAB: Service Portfolio
Figure 6.20 Hovione: Service Portfolio
Figure 6.21 Recipharm: Service Portfolio
Figure 6.22 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Figure 6.23 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Figure 6.24 Siegfried: Service Portfolio
Figure 6.25 Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Figure 6.26 Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Figure 6.27 CMIC Group: Service Portfolio
Figure 6.28 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Figure 6.29 Nectar Lifesciences: Service Portfolio
Figure 6.30 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Figure 6.31 WuXi AppTec: Service Portfolio
Figure 6.32 STA Pharmaceuticals (API Service Provider, WuXi AppTec): Service Portfolio
Figure 6.33 WuXi AppTec: Revenues (USD Million)
Figure 7.1 Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 7.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Processes
Figure 7.3 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Figure 8.1 Multipotentialite Service Providers, Heat Map Analysis: Distribution by Geography, Company Size and Year of Establishment
Figure 8.2 Pharmaceutical CMOs: Geographical Landscape Analysis by Location of Manufacturing Facilities
Figure 8.3 Pharmaceutical CMOs: Distribution by Geography, Company Size and Business Segment
Figure 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Figure 9.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Figure 9.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 9.4 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Figure 9.5 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 9.6 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 10.1 Pharmaceutical Contract Manufacturing: Market Forecast Approach
Figure 10.2 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Figure 10.3 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Figure 10.4 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.5 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.6 Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Figure 10.7 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (USD Billion)
Figure 10.8 Pharmaceutical Contract Manufacturing Market, 2018-2028: US, Base Scenario (USD Billion)
Figure 10.9 Pharmaceutical Contract Manufacturing Market, 2018-2028: Canada, Base Scenario (USD Billion)
Figure 10.10 Pharmaceutical Contract Manufacturing Market, 2018-2028: Mexico, Base Scenario (USD Billion)
Figure 10.11 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (USD Billion)
Figure 10.12 Pharmaceutical Contract Manufacturing Market, 2018-2028: Italy, Base Scenario (USD Billion)
Figure 10.13 Pharmaceutical Contract Manufacturing Market, 2018-2028: Germany, Base Scenario (USD Billion)
Figure 10.14 Pharmaceutical Contract Manufacturing Market, 2018-2028: France, Base Scenario (USD Billion)
Figure 10.15 Pharmaceutical Contract Manufacturing Market, 2018-2028: Spain, Base Scenario (USD Billion)
Figure 10.16 Pharmaceutical Contract Manufacturing Market, 2018-2028: UK, Base Scenario (USD Billion)
Figure 10.17 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Europe, Base Scenario (USD Billion)
Figure 10.18 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (USD Billion)
Figure 10.19 Pharmaceutical Contract Manufacturing Market, 2018-2028: India, Base Scenario (USD Billion)
Figure 10.20 Pharmaceutical Contract Manufacturing Market, 2018-2028: China, Base Scenario (USD Billion)
Figure 10.21 Pharmaceutical Contract Manufacturing Market, 2018-2028: Japan, Base Scenario (USD Billion)
Figure 10.22 Pharmaceutical Contract Manufacturing Market, 2018-2028: Australia, Base Scenario (USD Billion)
Figure 10.23 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Asia-Pacific, Base Scenario (USD Billion)
Figure 10.24 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (USD Billion)
Figure 10.25 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Figure 10.26 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Figure 10.27 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Figure 10.28 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product and Regions, Base Scenario (USD Billion)
Figure 10.29 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Figure 10.30 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Figure 10.31 Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.32 Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.33 Pharmaceutical Contract Manufacturing Market for Semi-Solid/Liquid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.34 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Figure 10.35 Pharmaceutical Contract Manufacturing Market for Tablets/Capsules/Blister Packing, 2018-2028: Base Scenario (USD Billion)
Figure 10.36 Pharmaceutical Contract Manufacturing Market for Glass/Plastic/Dropper Bottles, 2018-2028: Base Scenario (USD Billion)
Figure 10.37 Pharmaceutical Contract Manufacturing Market for Vials/Cartridges, 2018-2028: Base Scenario (USD Billion)
Figure 10.38 Pharmaceutical Contract Manufacturing Market for Ointments/Gels/Tubes, 2018-2028: Base Scenario (USD Billion)
Figure 10.39 Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028: Base Scenario (USD Billion)
Figure 10.40 Pharmaceutical Contract Manufacturing Market for Sachets/Pouches/Bags, 2018-2028: Base Scenario (USD Billion)
Figure 10.41 Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028: Base Scenario (USD Billion)
Figure 10.42 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Figure 10.43 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)
Figure 11.1 Pharmaceutical Contract Manufacturing SWOT Analysis: Overview
Figure 11.2 Pharmaceutical Contract Manufacturing SWOT Analysis: Strengths
Figure 11.3 Pharmaceutical Contract Manufacturing SWOT Analysis: Weaknesses
Figure 11.4 Pharmaceutical Contract Manufacturing SWOT Analysis: Opportunities
Figure 11.5 Pharmaceutical Contract Manufacturing SWOT Analysis: Threats
Figure 11.6 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 12.1 Future of Pharmaceutical Contract Manufacturing Market
Figure 12.2 Emerging Markets in Pharmaceutical Contract Manufacturing Industry
LIST OF TABLES
Table 4.1 Pharmaceutical CMOs: List of Industry Players
Table 4.2 Pharmaceutical CMOs: Information on Type of FDF Offered
Table 4.3 Pharmaceutical CMOs: Information on Scale of Operation
Table 4.4 Pharmaceutical CMOs: Information on Type of Service Offering
Table 4.5 Pharmaceutical CMOs: Information on Location of Manufacturing Facilities
Table 4.6 Pharmaceutical CMOs: Information on Type of Primary Packaging Form Offered
Table 5.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 5.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
Table 5.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 6.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
Table 6.2 AMRI: Manufacturing Facilities
Table 6.3 AMRI: Sterile Manufacturing Facilities
Table 6.4 AMRI: Recent Collaborations
Table 6.5 AMRI: Recent Expansions
Table 6.6 Catalent® Pharma Solutions: Manufacturing Facilities
Table 6.7 Catalent® Pharma Solutions: Recent Collaborations
Table 6.8 Catalent® Pharma Solutions: Recent Expansions
Table 6.9 DPT® Laboratories: Manufacturing Facilities
Table 6.10 DPT® Laboratories: Recent Collaborations
Table 6.11 DPT® Laboratories: Recent Expansions
Table 6.12 Patheon®: Manufacturing Facilities
Table 6.13 Patheon®: Recent Collaborations
Table 6.14 Patheon®: Recent Expansions
Table 6.15 Aenova Group: Manufacturing Facilities
Table 6.16 Aenova Group: Drug Product Manufacturing Capabilities
Table 6.17 Aenova Group: Recent Expansions
Table 6.18 Almac Group: Recent Collaborations
Table 6.19 Almac Group: Recent Expansions
Table 6.20 CordenPharma: Manufacturing Facilities
Table 6.21 CordenPharma: Recent Collaborations
Table 6.22 CordenPharma: Recent Expansions
Table 6.23 Fresenius Kabi: Manufacturing Facilities
Table 6.24 Fresenius Kabi: Packaging Capabilities
Table 6.25 Fresenius Kabi: Recent Collaborations
Table 6.26 Fresenius Kabi: Recent Expansions
Table 6.27 Glatt®: Manufacturing Facilities
Table 6.28 Glatt®: Recent Expansions
Table 6.29 Groupe SYNERLAB: Manufacturing Facilities
Table 6.30 Hovione: Manufacturing Facilities
Table 6.31 Hovione: Recent Collaborations
Table 6.32 Hovione: Recent Expansions
Table 6.33 Recipharm: Manufacturing Facilities
Table 6.34 Recipharm: Recent Collaborations
Table 6.35 Recipharm: Recent Expansions
Table 6.36 Siegfried: Manufacturing Facilities
Table 6.37 Siegfried: Recent Collaborations
Table 6.38 CMIC Group: Manufacturing Facilities
Table 6.39 CMIC Group: Recent Collaborations
Table 6.40 CMIC Group: Recent Expansions
Table 6.41 Nectar Lifesciences: Manufacturing Facilities
Table 6.42 WuXi AppTec: Manufacturing Facilities
Table 6.43 WuXi AppTec: Recent Collaborations
Table 6.44 WuXi AppTec: Recent Expansions
Table 7.1 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 7.2 List of Biopharmaceutical CMOs
Table 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 9.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 13.1 Ajinomoto Althea: Key Highlights
Table 13.2 Bachem: Key Highlights
Table 13.3 Sovereign Pharma: Key Highlights
Table 13.4 Batavia Biosciences: Key Highlights
Table 13.5 Polymun Scientific: Key Highlights
Table 13.6 Rentschler Biopharma: Key Highlights
Table 13.7 WACKER Biotech: Key Highlights
Table 13.8 CiVentiChem: Key Highlights
Table 13.9 Helsinn Group: Key Highlights
Table 13.10 Novasep: Key Highlights
Table 14.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Table 14.2 Pharmaceutical CMOs: Distribution by Geographical Location
Table 14.3 Pharmaceutical CMOs: Distribution by Company Size
Table 14.4 Pharmaceutical CMOs: Distribution by Type of Business Segment
Table 14.5 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Table 14.6 Pharmaceutical CMOs: Distribution by Scale of Operation
Table 14.7 Pharmaceutical CMOs: Distribution by Service Offerings
Table 14.8 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Table 14.9 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Table 14.10 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Table 14.11 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.12 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 14.13 Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Table 14.14 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Table 14.15 Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Table 14.16 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Table 14.17 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Table 14.18 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Table 14.19 Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Table 14.20 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Table 14.21 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Table 14.22 Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Table 14.23 Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Table 14.24 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Table 14.25 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Table 14.26 WuXi AppTec: Revenues (USD Million)
Table 14.27 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Table 14.28 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Table 14.29 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 14.30 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 14.31 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Table 14.32 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 14.33 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 14.34 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Conservative Scenario (USD Billion)
Table 14.35 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Table 14.36 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.37 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Table 14.39 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.40 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Conservative Scenario (USD Billion)
Table 14.41 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Table 14.42 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.43 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Conservative Scenario (USD Billion)
Table 14.44 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Table 14.45 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Optimistic Scenario (USD Billion)
Table 14.46 Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Table 14.47 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Base Scenario (USD Billion)
Table 14.49 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.50 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Conservative Scenario (USD Billion)
Table 14.51 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Base Scenario (USD Billion)
Table 14.52 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.53 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Conservative Scenario (USD Billion)
Table 14.54 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Base Scenario (USD Billion)
Table 14.55 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.56 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Table 14.57 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Table 14.58 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Conservative Scenario (USD Billion)
Table 14.59 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Table 14.60 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Types of API Product, Optimistic Scenario (USD Billion)
Table 14.61 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Conservative Scenario (USD Billion)
Table 14.62 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Base Scenario (USD Billion)
Table 14.63 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Type of API Product in North America, Optimistic Scenario (USD Billion)
Table 14.64 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Conservative Scenario (USD Billion)
Table 14.65 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Base Scenario (USD Billion)
Table 14.66 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Optimistic Scenario (USD Billion)
Table 14.67 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Conservative Scenario (USD Billion)
Table 14.68 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Base Scenario (USD Billion)
Table 14.69 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Optimistic Scenario (USD Billion)
Table 14.70 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Conservative Scenario (USD Billion)
Table 14.71 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Base Scenario (USD Billion)
Table 14.72 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Optimistic Scenario (USD Billion)
Table 14.73 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Conservative Scenario (USD Billion)
Table 14.74 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Table 14.75 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Optimistic Scenario (USD Billion)
Table 14.76 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Conservative Scenario (USD Billion)
Table 14.77 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Table 14.78 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Optimistic Scenario (USD Billion)
Table 14.79 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Conservative Scenario (USD Billion)
Table 14.80 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Table 14.81 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Optimistic Scenario (USD Billion)
Table 14.82 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Conservative Scenario (USD Billion)
Table 14.83 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Table 14.84 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Optimistic Scenario (USD Billion)
Table 14.85 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)

Executive Summary

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:


  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market till 2028, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines


  • Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the spray drying market in the long term.
  • Chapter 3 provides an introduction to the spray drying approach, including a detailed discussion on the principle/process of spray drying, highlighting the key steps associated with the process. It highlights the important applications of the technique and the various features that distinguish it from alternative drying technologies. The chapter also features a discussion on the various advantages and limitations associated with spray drying.
  • Chapter 4 provides an overview of the applications of spray drying in the pharmaceutical industry, from generation of extremely fine particles for pulmonary administration to large agglomerated powders for oral formulations. Specifically, the different applications discussed in the chapter include enhancement of solubility and bioavailability, formulation of inhalables, taste masking, development of controlled release formulations, and aseptic production of biopharmaceuticals.
  • Chapter 5 includes a comprehensive market overview, featuring information on various types of spray dryers used in the pharmaceutical industry. It provides information on their respective manufacturers (company size and year of establishment) and presents an analyses of spray dryers on the basis of inlet temperature, type of nozzle (fluid, pressure, rotary disc and others) used, size of the unit (lab, clinical and commercial), and atomizing gas (air, nitrogen and inert gases) used. Further, the chapter includes a discussion on companies that offer pharmaceutical spray drying services. It presents an analysis of various spray drying service providers on the basis of the geographical location of their facilities, scale of operation (lab, clinical and commercial) and information on cGMP statuses of their facilities.
  • Chapter 6 presents the key insights derived from the study. It features detailed 2X2 matrices, comparing the spray drying capabilities and the supplier power of different spray drying service providers. A similar analysis comparing the spray dryer portfolio and the establishment year of different manufacturers of spray dryers, is also included in the chapter. In addition, the chapter features a comprehensive geographical landscape analysis, which highlights the spray drying activity across the globe, in terms of presence of both manufacturers and service providers.
  • Chapter 7 features tabular profiles of the most active service providers (as identified in chapter 6) in the pharmaceutical industry. It highlights the expertise of these players in terms of their spray drying capabilities. Each profile provides a brief overview of the company, highlighting its employee strength (if available), its product/service portfolio, spray dryers used (if available) and the key developments related to spray drying (if available).
  • Chapter 8 provides detailed profiles of the most active spray dryer manufacturers (as identified in chapter 6) in the pharmaceutical industry. Each profile provides a brief overview of the company, its financial information (if available), its portfolio of spray dryers, recent developments, and a comprehensive future outlook.
  • Chapter 9 features a case study on lyophilization of biologics, the key competing technique to spray drying. The chapter elaborates on the steps involved in lyophilization, and lyophilization cycle development and optimization. It includes an exemplary list of service providers offering lyophilization services with information on location of facilities, type of drug candidates lyophilized, scale of operation and the containment systems utilized for such operations.
  • Chapter 10 presents a detailed analysis of the mergers and acquisitions that have taken place within this industry. The chapter highlights the information on the acquiring and the acquired company (headquarters and the ownership (public/private)), along with the year of acquisition, acquiring amount (if available), and the financial status of the acquired company, at the time of acquisition. It features a detailed ownership change matrix depicting the distribution of mergers and acquisitions across private firms, public firms and sole proprietorships. It also includes an evaluation of the financials of these deals (revenues of the acquired firms at the time of acquisition and their respective deal multiples).
  • Chapter 11 presents a comprehensive market forecast analysis, highlighting the future potential of the spray drying services market till the year 2028. The chapter also presents detailed market segmentation on the basis of geographical regions (North America, Europe, Asia Pacific and the rest of the world), type of industry (pharmaceuticals and biologics), and type of nozzles used in spray dryers (fluid nozzle, pressure nozzle, rotary disc atomizer, centrifugal nozzle and others).
  • Chapter 12 presents a detailed analysis capturing the key parameters and trends that are likely to influence the future of the spray drying market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall market.
  • Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
  • Chapter 14 is a collection of transcripts of interviews held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Sam de Costa (Stabilisation Projects Manager, Nova Laboratories), Manuel Leal (Business Development Director, Idifarma), Anonymous (Founder, India based Manufacturer).
  • Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
  • Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Companies Mentioned

  • 3P Biopharmaceuticals
  • A&Z Pharmaceutical
  • A.S. Joshi & Company
  • Aalto Scientific
  • Aarti Industries
  • Abbott
  • AbbVie
  • ABL
  • Abzena
  • Accra Pac India
  • ACES Pharma
  • Acino International
  • ACS Dobfar
  • Actiza Pharmaceutical
  • Adar Biotech
  • Admac Formulations
  • Aenova
  • Aesica Pharmaceuticals
  • Affinity Life Sciences
  • Afton Scientific
  • Agno Pharma
  • AiPing Pharmaceutical
  • Air Water
  • Ajinomoto Althea
  • Ajinomoto OmniChem
  • Akorn
  • Akums Drugs & Pharmaceuticals
  • Al Bahja Group
  • Aland (Jiangsu) Nutraceutical
  • Albany Molecular Research (AMRI)
  • Albatros Pharmaceuticals
  • Albemarle
  • AlbyPharma
  • Alcami
  • Alcatel-Lucent
  • Aldevron
  • Alembic Pharmaceuticals
  • Alkermes®
  • AllChem Laboratories
  • Alliance Medical Products
  • Almac Pharma
  • Alpax Pharmaceutical
  • Alphora Research
  • Alps Pharmaceutical
  • Altaris Capital Partners
  • ALTHEA Pharma
  • Amanta Healthcare
  • Amatsigroup
  • Ambica Pharma Sales
  • AmbioPharm
  • AMEGA Biotech
  • American Antibiotics
  • Amgen®
  • Ami Lifescience
  • Amman Pharmaceutical Industries
  • Amneal Pharmaceuticals
  • Amoli Organics
  • AMPAC Fine Chemicals
  • Angelini
  • Anhui Biochem United Pharmaceutical
  • Ankur Drugs and Pharma
  • Anogen
  • Anqiu Lu'an Pharmaceutical
  • apceth Biopharma
  • Apex Pharmaceuticals
  • Apicore Pharmaceuticals
  • Apiscent Labs
  • APL
  • Apotex Fermentation
  • Aptuit
  • Arabio
  • Arbro Pharmaceuticals
  • Arch Pharmalabs
  • Arevipharma
  • Arran Chemical Company
  • Arvincare
  • Asahi Glass Company (AGC)
  • Asahi Kasei Finechem
  • Ashford Pharmaceutical Laboratories
  • Aspen Pharmacare Holdings
  • Aster Pharma
  • Asymchem Laboratories
  • ATRA Pharmaceuticals
  • AURA Biotechnologies
  • Aurelius
  • Aurobindo Pharma
  • Ausler Snovy Healthcare
  • AustarPharma
  • Austin Pharmaceuticals
  • AutekBio
  • Avecia
  • Avid Bioservices
  • Avra Laboratories
  • Avyukt Pharmaceuticals
  • Axa Parenterals
  • Baccinex
  • Bachem
  • Bal Pharma
  • Batavia Biosciences
  • Bausch & Lomb
  • Baxil Pharma
  • Baxter BioPharma Solutions
  • Bayer
  • BCN Peptides
  • Beach Products
  • Becton Dickinson
  • Beijing Second Pharmaceutical
  • Belcher Pharmaceuticals
  • Belco Pharma
  • Beltapharm
  • Bennet Pharmaceuticals
  • BePharBel
  • Beximco Pharmaceuticals
  • Bharat Pharmaceuticals
  • Bharat Serums and Vaccines
  • BIBITEC
  • BINEX
  • Bio Elpida
  • BioCell
  • BioClin Laboratories
  • Biocon
  • BioConnection
  • BIOFABRI
  • Bio-Garten
  • Biogen
  • Biological E
  • BioMARC
  • Biomatik
  • Biomay
  • BIOMEVA
  • Bio-Pharm
  • BioPharmaceuticals Australia
  • Bioserv
  • BioSynergy
  • Bio-Synthesis
  • Biotech Vision Care
  • BioTechLogic
  • BioTechnique™
  • Biotechpharma
  • Biovectra
  • Biovian
  • Bluepharma
  • Blueprint Medicines
  • Boehringer Ingelheim BioXcellence
  • Bonarum Pharma
  • Brammer Bio
  • Brassica Pharma
  • Brazilian Health Regulatory Agency (ANVISA)
  • Broad Institute of MIT and Harvard
  • Broad Pharmaceutical
  • Bruker Daltonics
  • Bruschettini
  • Bryllan
  • BSP Pharmaceuticals
  • C & O Pharmaceutical Technology
  • Cadila Pharmaceuticals
  • Calyx Chemicals & Pharmaceuticals
  • Cambrex
  • Capgemini
  • Caplin Point Laboratories
  • Capsugel®
  • CARBOGEN AMCIS
  • Catalent® Pharma Solutions
  • Cayman Chemical
  • Cell and Gene Therapy Catapult
  • Cell Culture Company
  • Cell Essentials
  • Cell Therapies
  • CELLforCURE
  • Cellin Technologies
  • Celltech
  • Celltrion
  • Cellular Therapeutics
  • Celonic
  • Cenexi
  • Centaur Pharmaceuticals
  • Center for Biocatalysis and Bioprocessing, The University of Iowa
  • Central Drugs Standard Control Organization (CDSCO)
  • Century Pharmaceuticals
  • CEPiA Sanofi
  • Cerbios-Pharma
  • CF Pharma
  • Charles River Laboratories
  • Chartwell Pharmaceuticals
  • ChemCon
  • Chemi Peptides
  • Chemigran
  • ChemPacific
  • ChemPartner
  • Cherokee Pharma
  • Chifeng Arker Pharmaceutical Technology
  • China Chemical & Pharmaceutical (CCPC)
  • China Food and Drug Administration (CFDA)
  • Chiral Biosciences
  • Chirogate International
  • Chongqing Huapont Pharmaceutical
  • Chromo Laboratories
  • Chunghwa Chemical Synthesis & Biotech
  • CinnaGen
  • Ciron Group
  • Cirrus Pharmaceuticals
  • CiVentiChem
  • Clinical Trial Consultants (CTC)
  • Cloud Holdings
  • CMC Biologics
  • CMC Milling
  • CMIC Group
  • Coating Place
  • Cobra Biologics
  • COC Farmaceutici
  • Cody Laboratories
  • Cognate BioServices
  • Columbia University
  • Combino Pharm
  • Comprehend Systems
  • Concord Biotech
  • Concord Drugs
  • Confab Laboratories
  • Contract Coating
  • Contract Pharmacal
  • Cook Pharmica
  • Corden BioChem
  • CordenPharma
  • CoreRx®
  • CP Pharmaceuticals
  • Creative® Biolabs
  • CRELUX
  • Cris Pharma
  • Crown Laboratories
  • CTX Lifesciences
  • Custom Pharmaceuticals
  • Cyalume® Speciality Products
  • Cytovance® Biologics
  • Daiichi Sankyo
  • Daito Pharmaceutical
  • Dalton Pharma Services
  • Delavau Pharmaceutical Partners
  • Delmar Chemicals
  • Delpharm
  • Delta Laboratories
  • Dermopartners
  • DEVA Holding
  • DFB Pharmaceuticals
  • Dhruv Life Sciences
  • Dipharma Francis
  • Dishman Group
  • Divis Laboratories
  • DM Pharma
  • dmBio
  • DOTTIKON EXCLUSIVE SYNTHESIS
  • Douglas Pharmaceuticals
  • DPT® Laboratories
  • Dr. Reddy's Custom Pharmaceutical Services (CPS)
  • Dupen Laboratories
  • Dwarkesh Pharmaceuticals
  • Eagle Pharmaceuticals
  • Eden Healthcare
  • Ei-A Pharmaceutical SolutionWorks™
  • EirGen Pharma
  • EirGenix
  • EL Laboratories
  • Elite Pharmaceuticals
  • Elli Lilly
  • Embio
  • Emcure Pharmaceuticals
  • Emergent Biosolutions®
  • Eminent Healthcare
  • Enaltec Labs
  • Encap Drug Delivery
  • Enrich Pharma
  • Entema Laboratorios
  • Entod Pharmaceuticals
  • Epic Pharma
  • EPTEK Technology
  • Ercros
  • Eriochem
  • Erregierre
  • Esteve Química
  • Ethypharm
  • EuBiologics
  • EUCODIS Bioscience
  • EUFETS
  • Eurogentec
  • Euro-Med Laboratories
  • European Medicines Agency (EMA)
  • Euticals
  • Evonik Industries
  • Evotec
  • Excella
  • Exela Pharma Sciences
  • Exostar
  • Exova SL Pharma Labs
  • F.I.S. Fabbrica Italiana Sintetici
  • Famar
  • Famy Care
  • Fareva®
  • Farmabios®
  • Farmak
  • Farmhispania Group
  • Farmigea
  • FDC
  • Fermion
  • Ferndale Laboratories
  • Finecure Pharmaceuticals
  • FineTech Pharmaceuticals
  • Flamingo Pharmaceuticals
  • Flamma
  • Fleming Laboratories
  • Fluid Energy Processing and Equipment
  • Fresenius Kabi
  • Fresenius Kabi Product Partnering
  • FUJIFILM Diosynth Biotechnologies
  • Fujimoto Chemicals
  • Fusion Antibodies
  • Future Pak
  • G&W Laboratories
  • Gadea Pharmaceutical Group
  • Gala Biotech
  • Galentic Pharma
  • Gattefossé
  • GD Pharma
  • GE Healthcare
  • Gedeon Richter
  • Gemini PharmChem Mannheim
  • Gene Transfer Vector Core (GTVC)
  • GeneCure Biotechnologies
  • Genentech
  • GenIbet Biopharmaceuticals
  • Gerresheimer
  • Getz Pharma Research
  • Gland Pharma
  • Glatt®
  • GlaxoSmithKline (GSK)
  • Glenmark Pharmaceuticals
  • Global Pharmatech
  • Glochem Industries
  • Glycotope Biotechnology
  • GNH India
  • goBalto
  • Goodwin Biotechnology
  • GP Pharm
  • Grand River Aseptic Manufacturing
  • Granules India
  • Granules Omnichem
  • GreenPak Biotech
  • Grindeks
  • Groupe PARIMA
  • Groupe SYNERLAB
  • Grupo Farmasierra
  • GTCR
  • GTP Technology
  • Guardian Drug Company
  • Hainan Poly Pharm
  • Hainan Visum Pharmaceutical
  • HALIX
  • Halo Pharma
  • Handok
  • Hanford Pharmaceuticals
  • Hangzhou Hysen Pharma
  • Hangzhou Imaginechem
  • Hangzhou Panyu Chemical
  • Hanuchem Laboratories
  • HD Biosciences
  • Health Biotech
  • Health Canada
  • Healthcare Pharmaceuticals
  • Healthy Life Pharma
  • Helios Pharmaceuticals
  • Helsinn Group
  • Hetero Drugs
  • Hewlett-Packard®
  • HighRes Biosolutions
  • Hikal
  • Hikma Pharmaceuticals
  • Histocell
  • hollomet®
  • Hong Kong Institute of Biotechnology
  • Honson Pharmatech Group
  • Horizon Pharma
  • Hospira One2One
  • Hovione
  • Howard Hughes Medical Institute (HHMI)
  • Hritik Chemicals
  • Hubei Biocause Pharmaceutical
  • IBM®
  • Icagen
  • ICROM
  • IDT Australia
  • IDT Biologika
  • Illumina
  • Indena
  • Indian Immunologicals
  • Indoco Remedies
  • Ind-Swift Laboratories
  • Ingenus Pharmaceuticals
  • Inke
  • Inno Biologics
  • Innova Captab
  • Institute for Advanced Study (IAS)
  • INSYS Therapeutics
  • Intas Pharmaceuticals
  • Integrity Bio
  • International Chemical Investors Group (ICIG)
  • International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)
  • Interquim
  • Invent Farma
  • inVentiv Health
  • IPC Process-Center
  • i-Pharmaceuticals
  • Istituto Biochimico Italiano Giovanni Lorenzini
  • IVAX Pharmaceuticals
  • J.B. Chemicals & Pharmaceuticals
  • Janssen Pharmaceuticals
  • Japan CMO Association (JCMOA)
  • JGL
  • JHL Biotech
  • Johnson & Johnson
  • Johnson Matthey
  • JSC Olainfarm
  • Jubilant Life Sciences
  • Julphar Gulf Pharmaceutical Industries
  • Juno Therapeutics
  • JW Biotechnology
  • Jyoti Capsulations
  • KABS Pharmaceutical Services
  • Kamat Pharmatech
  • Kancera
  • Karolinska University Hospital
  • Katsura Chemical
  • KBI Biopharma
  • Kekule Pharma
  • Kemwell Biopharma
  • Keryx Biopharmaceuticals
  • Kilitch Healthcare
  • Kongo Chemical
  • Korten
  • KP Pharmaceutical Technology
  • Krebs Biochemicals & Industries
  • KRS Global Biotechnology
  • Kyowa Pharma Chemical
  • Laboratório Edol
  • Laboratorios Farmacéuticos ROVI
  • Laboratorios Lesvi
  • Laboratorios SALVAT
  • Laccure
  • Lameplast Group
  • LAMPIRE Biological Laboratories
  • Lannett
  • Laurus Labs
  • Lenovo™
  • Lenus LifeCare
  • LFB BIOMANUFACTURING
  • LIDDS™
  • Life Sciences Solutions
  • Life Technologies™
  • Lifekyor Pharmaceuticals
  • Lloyd Laboratories
  • LOBA Feinchemie
  • Logos Pharma
  • Lomapharm®
  • Long Pharmaceuticals
  • Lonza
  • LSNE Contract Manufacturing
  • Luina Bio
  • Luitpold Pharmaceuticals
  • Lyne Laboratories
  • MabPlex
  • MacFarlan Smith
  • Macter International
  • Madras Pharmaceuticals
  • Maine Biotechnology Services
  • MAKCUR Laboratories
  • Malik Lifesciences
  • Malladi Drugs & Pharmaceuticals
  • Manav Drugs
  • Marchesini Group
  • Marksans Pharma
  • Massachusetts Institute of Technology
  • MassBiologics
  • MaSTherCell
  • Maxcure Nutravedics
  • Maya Biotech
  • Mayne Pharma Group
  • McGuff Pharmaceuticals
  • MDC Pharmaceuticals
  • Meda Pharmaceuticals
  • Medical Products Laboratories
  • Medichem
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Medicines Control Council (MCC)
  • Medilux Laboratories
  • Mediwin Pharmaceuticals
  • Medix Biochemica
  • MedPharm
  • Menadiona
  • Menarini Biotech
  • Mercator Pharmaceutical Solutions
  • Merck
  • Meridian Life Science
  • Meridian Medicare
  • Merro Pharmaceutical
  • Metrics Contract Services
  • Metrochem API
  • Micro Labs
  • MicroBiopharm Japan
  • Micro-Sphere
  • Mikart
  • Ministry of Food and Drug Safety (MFDS)
  • Ministry of Health, Labour and Welfare (MHLW)
  • Mipharm
  • Mitim
  • MSN Laboratories
  • Multi-Pack Solutions
  • Murty Pharmaceuticals
  • Mycenax Biotech
  • Mylan®
  • Nakoda Chemicals
  • Nanjing Pharmatechs
  • NATCO Pharma
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • Nectar Lifesciences
  • NEISS Labs
  • Nephron Pharmaceuticals
  • NerPharMa
  • Neuland Laboratories
  • New York Center for Nanomedicine Research
  • Nexgen Pharma
  • Nextar Chempharma Solutions
  • Nimbles Biotech
  • Ningbo Renjian Pharmaceutical Group
  • Nippon Rika Technologies
  • Nipro Patch
  • Nitin Lifesciences
  • Nitto Avecia Pharma Services
  • Nitto Denko Avecia
  • Nivon Specialties
  • Norac Pharma
  • North Star Processing
  • Norwegian Institute of Public Health
  • Norwich Pharma Services
  • Nova Laboratories
  • NovaMed Pharmaceuticals
  • Novartis
  • Novasep
  • Novel Laboratories
  • Novex Innovations
  • Nutragen Pharma
  • NutraLab
  • NVRON Life Science
  • Oakwood Laboratories
  • Oasis Laboratories
  • Oceanic Pharmachem
  • OctoPlus
  • Olon
  • Oman Pharmaceutical Products
  • Omnia Biologics
  • Onco Generics
  • Oncotec Pharma Produktion
  • OPKO Health
  • Optel Vision
  • Orchid Pharma
  • Orient EuroPharma
  • Orient Pharma
  • Orion
  • Orofino Pharmaceuticals Group
  • Oso BioPharmaceuticals Manufacturing
  • Oxford BioMedica
  • P&R Holding
  • Pan American Health Organization (PAHO)
  • Panacea Biotec
  • PannonPharma
  • Parabolic Drugs
  • Paragon® Bioservices
  • Particle Sciences
  • Patheon®
  • PB-L Productos Bio-Lógicos
  • PCI Synthesis
  • PCT Cell Therapy
  • Pegasus Farmaco India
  • Penn United Industries
  • Perrigo®
  • Pfizer
  • Pfizer CentreOne
  • Pharma Stulln
  • PharmaCell
  • Pharmaceutical Associates
  • Pharmaceutical Manufacturing Research Services (PMRS)
  • Pharmaceutical Medical Devices Agency (PMDA)
  • Pharmaceutics International (Pii)
  • Pharmacia & Upjohn
  • PharmAgra Labs
  • Pharma-Q
  • Pharmascience
  • Pharmasol
  • Pharmatronic
  • PharmaZell
  • Pharmedartis
  • Pharmer
  • Pharmicell
  • Phenom-World
  • Phytex Australia
  • Phyton Biotech
  • Pierre Fabre
  • Pillar5 Pharma
  • Pinewood Healthcare
  • Piramal Pharma Solutions
  • PiSA Farmaceutica
  • Pisgah Laboratories
  • PlasmidFactory
  • PMC Isochem
  • Polpharma
  • Polymun Scientific
  • PolyPeptide Group
  • Polysciences
  • Porton Fine Chemicals
  • Praxis Pharmaceutical
  • Precision Antibody
  • Preet Remedies Group
  • PREMAS Biotech
  • Prima BioMed
  • PrimaPharma
  • Prisha Healthcare
  • ProBioGen
  • Procaps
  • Procos
  • Profectus BioSciences
  • ProJect Pharmaceutics
  • ProMab Biotechnologies
  • Proton Pharma
  • Provizer Pharma
  • PRWT Services
  • PT. ETHICA Industri Farmasi
  • Pure & Cure Healthcare
  • PX'Therapeutics
  • Pyramid Laboratories
  • QS Pharma
  • Qualigen
  • Qualiphar-Gifrer
  • Qualitron Bio Medica
  • Quality Chemical Laboratories
  • Qualtra Pharmaceuticals
  • Quay Pharma
  • Que Pharma
  • Radico Remedies
  • Rafarm
  • Ramsey Design Group
  • Rank Group
  • Recipharm
  • Redwing Pharma
  • Regis Technologies
  • Reliable Biopharmaceutical®
  • Reliance Life Sciences
  • Remington Pharmaceuticals
  • Renaissance Acquisition Holdings
  • Rentschler Biopharma
  • ResearchPoint Global
  • Richter-Helm BioLogics
  • RiconPharma
  • RIVOPHARM
  • RL Fine Chem
  • Robert Wood Johnson Medical School
  • Roche
  • Rommelag
  • Rompharm
  • Roslin Cell Therapies
  • Rottendorf Pharma
  • Rubicon Research
  • Rusan Pharma
  • SAFC Pharma™
  • SAI Life Sciences
  • Salvus Pharma
  • Sandoz
  • Sanico
  • SANOCHEMIA Pharmazeutika
  • Sanquin Pharmaceutical Services
  • Sanwa Kagaku Kenkyusho
  • Sarvodaya Drugs & Pharmaceuticals
  • Sarvotham Care
  • Sato Pharmaceutical
  • SAVA Healthcare
  • Savior Lifetec
  • Schering-Plough
  • SCI Pharmtech
  • Scientific Protein Laboratories
  • ScinoPharm
  • SEA Vision
  • Seacross Pharmaceuticals
  • Sekisui Medical
  • Selvok Pharmaceutical
  • Senn Chemicals
  • Sensilab®
  • Sentiss Pharma
  • Sesderma Group
  • Shandong Xinhua Pharmaceutical
  • Shanghai Pharmaceuticals Holding
  • Shanghai Shyndec Pharmaceutical
  • Sharon Bio-Medicine
  • Shasun Pharmaceuticals
  • Shilpa Medicare
  • Shionogi
  • Shire
  • Sichuan Huiyu Pharmaceutical
  • Siegfried
  • Sigmapharm Laboratories
  • SignaGen Laboratories
  • Singota Solutions
  • Sinopharm
  • Sirio Pharma
  • SM Pharmaceuticals
  • Smruthi Organics
  • SMS Pharmaceuticals
  • Societa Italiana Medicinali Scandicci
  • Softgel Healthcare
  • Softigel
  • SOHO Global Health
  • Solitaire Pharmacia
  • Sovereign Pharma
  • Square Pharmaceuticals
  • Sricure Herbs
  • ST Pharm
  • STA Pharmaceutical
  • STADA Arzneimittel
  • Stason Pharmaceuticals
  • Stericon
  • Steril-Gene Life Sciences
  • Strides Shasun
  • Sunrise International Labs
  • Sunrise Pharma
  • Sunways
  • Suven Life Sciences
  • Suzuken
  • Swiss Pharma
  • Symbiosis Pharmaceutical Services
  • Symed Labs
  • Synbias Pharma
  • SynCo Bio Partners
  • Syncom Healthcare
  • Syngene International
  • SYNLAB Group
  • Syntech Pharmachem
  • Synthokem Labs
  • Syntonix Biofarm
  • Tahira Industries India
  • Tai Heng Industry
  • Takara Bio
  • Tara Innovations
  • Tedor Pharma
  • Teligent
  • TESARO
  • Teva Active Pharmaceutical Ingredients (TAPI)
  • The Carlyle Group
  • The Native Antigen Company
  • The Ritedose
  • Theon Pharmaceuticals
  • Therapeutic Goods Administration (TGA)
  • Therapure Biopharma
  • Thermo Fisher Scientific
  • Tianjin Pharmaceutical Group
  • Tillotts Pharma
  • Time-Cap Labs
  • Titan Pharma
  • TOLMAR
  • Tonus-Les
  • Torrent Pharmaceuticals
  • Toyobo Biologics
  • TraceLink
  • TranXenoGen
  • trenzyme
  • Tubilux Pharma
  • Tyger Scientific
  • Ultra Tab Laboratories
  • Ultratech India
  • Unibiotech Formulations
  • Unichem Laboratories
  • Unimark Remedies
  • Union Quimico Farmaceutica (UQUIFA)
  • Unison Chemical Works
  • United States Food and Drug Administration (USFDA)
  • University of Alabama
  • University of Minnesota
  • University of Nebraska
  • University of Newcastle
  • University of Pennsylvania
  • University of Utah
  • UPM Pharmaceuticals
  • Uppsala University Hospital
  • URSAPHARM Arzneimittel
  • US Pharma Lab
  • USV
  • Valeant Pharmaceuticals International
  • Veeva Systems
  • Vendiz Pharmaceuticals
  • VerGo Pharma Research
  • Vertex Pharmaceuticals
  • Vetter Pharma
  • VGXI
  • Vibalogics
  • Vigene Biosciences
  • Virbac
  • Virovek
  • Vista Biologicals
  • Vital Health Care
  • Vivimed Labs
  • VUAB Pharma
  • WACKER Biotech
  • Waisman Biomanufacturing
  • Wanbury
  • WellSpring Pharmaceutical
  • West Pharmaceutical Services
  • WeylChem Group
  • Wilmington PharmaTech
  • Windlas Healthcare
  • Wintac
  • Wisdom Pharmaceutical
  • Wockhardt
  • World Health Organization (WHO)
  • World Intellectual Property Organization (WIPO)
  • World Trade Organization (WTO)
  • Wuhan Biocause Pharmaceutical Development
  • WuXi AppTec
  • WuXi NextCODE
  • Xellia Pharmaceuticals
  • Xi'an Lijun Pharmaceutical
  • XtalPi
  • Xttrium Laboratories
  • YaoPharma
  • Yash Pharma Laboratories
  • Yung Zip Chemical
  • Zach System
  • Zambon
  • Zenacts Pharma
  • Zenara Pharma
  • Zenith Healthcare
  • ZenLabs Ethica
  • ZheJiang Apeloa JiaYuan Pharmaceutical
  • Zhejiang Changming Pharmaceutical
  • Zhejiang Cheng Yi Pharmaceutical
  • Zhejiang Excel Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang Huangyan Fine Chemical Group
  • Zhejiang Jingxin Pharmaceutical
  • Zydus BSV Pharma
  • Zydus Cadila

Methodology

 

 

Loading
LOADING...